<!DOCTYPE html>
<!--
==============================================================================
           "GitHub HTML5 Pandoc Template" v2.1 — by Tristano Ajmone           
==============================================================================
Copyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:

- https://github.com/tajmone/pandoc-goodies

The CSS in this template reuses source code taken from the following projects:

- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):
  https://github.com/sindresorhus/github-markdown-css

- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):
  http://primercss.io/

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
The MIT License 

Copyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)
Copyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)
Copyright (c) 2017 GitHub Inc.

"GitHub Pandoc HTML5 Template" is Copyright (c) Tristano Ajmone, 2017, released
under the MIT License (MIT); it contains readaptations of substantial portions
of the following third party softwares:

(1) "GitHub Markdown CSS", Copyright (c) Sindre Sorhus, MIT License (MIT).
(2) "Primer CSS", Copyright (c) 2016 GitHub Inc., MIT License (MIT).

Permission is hereby granted, free of charge, to any person obtaining a copy
of this software and associated documentation files (the "Software"), to deal
in the Software without restriction, including without limitation the rights
to use, copy, modify, merge, publish, distribute, sublicense, and/or sell
copies of the Software, and to permit persons to whom the Software is
furnished to do so, subject to the following conditions:

The above copyright notice and this permission notice shall be included in all
copies or substantial portions of the Software.

THE SOFTWARE IS PROVIDED "AS IS", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR
IMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,
FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE
AUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER
LIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,
OUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE
SOFTWARE.
==============================================================================-->
<html>
<head>
  <meta charset="utf-8" />
  <meta name="generator" content="pandoc" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes" />
  <title>Osteoarthritis  v2.0 MeG-CLS-042</title>
  <style type="text/css">
@charset "UTF-8";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,"Segoe UI",Helvetica,Arial,sans-serif,"Apple Color Emoji","Segoe UI Emoji","Segoe UI Symbol";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:""}.markdown-body hr::after{display:table;clear:both;content:""}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,"Liberation Mono",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,"Liberation Mono",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:" "}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,"Liberation Mono",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:""}.markdown-body::after{display:table;clear:both;content:""}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}
  </style>
  <style type="text/css">code{white-space: pre;}</style>
  <!--[if lt IE 9]>
    <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js"></script>
  <![endif]-->
</head>
<body>
<article class="markdown-body">
<h1 id="osteoarthritis">Osteoarthritis</h1>
<h2 id="executive-summary"><em>Executive summary</em></h2>
<h2 id="introduction">Introduction</h2>
<p>Osteoarthritis (OA) is a common condition resulting in mechanical and biological dysfunction of joints leading to loss of cartilage, sclerosis and eburnation of the subchondral bone, osteophytes, and subchondral cysts. It is characterized by joint pain, stiffness, and functional limitation. Key risk factors include age over 50 years, female sex, obesity and occupation.</p>
<h2 id="target-users">Target users</h2>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Nurses</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Doctors</p>
</div></li>
</ul>
<h2 id="target-area-of-use">Target area of use </h2>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Gate Clinic</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>OPD</p>
</div></li>
</ul>
<h2 id="key-areas-of-focus-new-additions-changes">Key areas of focus / New additions / Changes </h2>
<p>This guideline provides information on the diagnosis and treatment of osteoarthritis. Patients with typical presentation do not require further workup. Treatment involves both non-pharmacologic and pharmacological measures.</p>
<h2 id="limitations">Limitations</h2>
<p>Physical and occupational therapy services are not available in our facility. Surgical therapy is available privately within The Gambia<strong>.</strong></p>
<h2 id="presenting-symptoms-and-signs">Presenting symptoms and signs</h2>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Pain relating to physical activity and weight bearing activity.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Functional difficulties such as knee giving way.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Commonly affects knees, hips, hands, lumbar and cervical spine.</p>
</div></li>
</ul>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Unlikely to involve the ankles (which helps in differential diagnosis)</p>
</div></li>
</ul>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Morning stiffness is rare and would require further investigation (if present for more than 30 minutes.)</p>
</div></li>
</ul>
<h2 id="examination-findings">Examination findings</h2>
<ul>
<li><h2 id="oa-can-cause-pain-along-the-joint-line.">OA can cause pain along the joint line.</h2></li>
<li><div data-custom-style="List Paragraph">
<p>Crepitus (palpable &amp; sometimes audible creaking of joint in active and passive movement.)</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Bony deformity (especially in the hands there is enlargement of the proximal interphalangeal (PIP) and distal interphalangeal (DIP) joints. In advanced knee osteoarthritis there may be new bone formation causing bony swelling.)</p>
</div></li>
</ul>
<h3 id="differential-diagnoses">Differential diagnoses</h3>
<p><strong>Rheumatoid arthritis</strong> - small joint symmetrical polyarthritis, with prolonged morning stiffness. Exacerbations can be associated with malaise and feeling generally unwell. May have raised ESR, raised CRP and erosive changes on X-ray.</p>
<p><strong>Psoriatic arthritis</strong> – Associated with psoriasis but can occur without skin lesions. It usually affects DIP joints (asymmetrical) and shows erosive changes on X-ray.</p>
<p><strong>Gout &amp; Pseudogout</strong> – Normally more acute onset with hot, swollen, tender joints. Gout affects first metatarsophalangeal joint (big toe pain), while pseudogout most commonly affects wrist and knee. Aspiration of the joint can diagnose this.</p>
<p><strong>Avascular necrosis</strong> –Consider if patients with history of corticosteroid use or young adults with sickle cell disease. Half of these cases will have associated effusion.</p>
<p><strong>Bursitis</strong> (Greater trochanteric gives pain over lateral aspect of the hip, pes anserine bursitis gives pain over medial aspect of the knee.)</p>
<h2 id="investigations">Investigations</h2>
<p>Generally, no investigations are required if ALL the following are true</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Over 50</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>No morning stiffness (or less than 30 minutes.)</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Crepitus</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Joint line tenderness</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Bony enlargement (in knee) or classical Heberden or Bouchard nodes (in hands)</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>No palpable warmth</p>
</div></li>
</ul>
<p>Where there is doubt:</p>
<ol type="1">
<li><div data-custom-style="List Paragraph">
<p>X-ray of affected joint – Will show new bone formation (osteophytes), joint space narrowing, and subchondral sclerosis and cysts.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>ESR: ordered if inflammatory arthritis is suspected. In OA, ESR should be less than 40 mm/hour</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Rheumatoid Factor (RF) – If inflammatory arthritis is suspected.</p>
</div></li>
</ol>
<p>Uric acid is not generally indicated but may be worthwhile in conjunction with joint aspiration when calculating risk of gout over septic arthritis in hot, red swollen joint.</p>
<h2 id="management">Management</h2>
<h3 id="non-pharmacological-management">Non pharmacological management</h3>
<p>Weight loss (goal of loss of 5-10% of overweight or obese results in 50% reduction in pain) and exercise e.g. muscle strengthening, walking, cycling, yoga, hamstring stretches, aquatic exercises, Tai Chi are key aspects of management. Running or jumping is discouraged to avoid further joint damage.</p>
<p>Physiotherapy including quadriceps exercises is helpful.</p>
<p>Occupational therapy – supportive footwear, knee brace and stick/cane on contralateral side of arthritic joint.</p>
<h3 id="pharmacological">Pharmacological </h3>
<p>1<sup>st</sup> line: Topical NSAIDs – Diclofenac gel two to four times daily + non-pharmacological management</p>
<p>2<sup>nd</sup> line: Oral treatment – NSAIDS for shortest possible duration (Ibuprofen 200-400mg TDS) + paracetamol + 1<sup>st</sup> line measures. (Consider gastroprotection with omeprazole when prescribing NSAIDS) .</p>
<p>3<sup>rd</sup> line: Codeine (15-60mg QDS) + NSAIDS + paracetamol + 1<sup>st</sup> line measures.</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Opioids only used for a short duration in patients with severe and disabling symptoms due to potential side effects e.g. nausea, dizziness and drowsiness.</p>
</div></li>
</ul>
<p>4<sup>th</sup> line: May include the addition of stronger opioids – such as Morphine Slow-Release Tablets (MST).</p>
<p>Paracetamol has only negligible, non-clinically significant benefits for pain relief compared to placebo. Combined with the risk of harm, long-term use is not recommended.</p>
<p>Intra-articular methylprednisolone injections during any line of management is not routinely recommended due to its short duration of effects (approximately 4 weeks) and evidence it may have deleterious effects on hyaline cartilage and may accelerate OA progression. These may be available in some private clinics locally.</p>
<p>In addition, there is a lack of clear evidence recommending insoles or nutritional supplements e.g. glucosamine, chondroitin, vitamin D, diacerein, calcium or fish oil.</p>
<p>Patients unable to gain adequate/ acceptable pain control with functional impairment may wish to seek referral for surgical management i.e. total joint replacement which is available privately.</p>
<h2 id="key-issues-for-nursing-care">Key Issues for Nursing care</h2>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Patients should be advised about weight loss and exercise.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Anyone with red, hot , or swollen joint should be seen/discussed with a doctor in OPD</p>
</div></li>
</ul>
<h2 id="references">References</h2>
<p>Badlissi F. Osteoarthritis. BMJ Best Practice. May 2018. Available from: <a href="https://bestpractice.bmj.com/topics/en-us/192"><span data-custom-style="Hyperlink">https://bestpractice.bmj.com/topics/en-us/192</span></a> Accessed: June 2018</p>
<p>National Institute of Clinical excellence (NICE) clinical guideline [CG177] Osteoarthritis Care and Management February 2014</p>
<table>
<thead>
<tr class="header">
<th><strong>Written by:</strong></th>
<th>Name: David Burgess</th>
<th>Date: 01 June 2018</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Reviewed by:</strong></td>
<td>Name: Fatai Akemokwe</td>
<td>Date: 11 June 2018</td>
</tr>
<tr class="even">
<td></td>
<td>Name: Caryssa Yan</td>
<td>Date: 6 July 2020</td>
</tr>
<tr class="odd">
<td></td>
<td>Name: Bubacarr Susso</td>
<td>Date: 14 July 2020</td>
</tr>
<tr class="even">
<td><strong>Version:</strong></td>
<td><strong>Change history:</strong></td>
<td><strong>Review due date:</strong></td>
</tr>
<tr class="odd">
<td>1.0</td>
<td>New document</td>
<td>31 July 2020</td>
</tr>
<tr class="even">
<td>1.1</td>
<td>Executive summary added</td>
<td>31 July 2020</td>
</tr>
<tr class="odd">
<td>2/.0</td>
<td>Update to the management</td>
<td>01 November 2022</td>
</tr>
<tr class="even">
<td>Review Comments (<em>if applicable)</em></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
</article>
</body>
</html>
